#POLB Poolbeg Pharma PLC – Result of upsized oversubscribed BookBuild Offer May 23, 2025 – Posted in: Poolbeg Pharma (POLB)

Result of upsized and oversubscribed BookBuild Offer ·      Conditionally raised gross proceeds of £150,000 from the upsized and oversubscribed BookBuild Offer ·      Total gross proceeds conditionally raised pursuant to the Fundraising therefore increased to £4.865 million ·      Use of net proceeds from the Fundraising: o  Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) o  Oral GLP-1 proof-of-concept clinical trial o  Cash runway extended through to 2027 Poolbeg Pharma…

Continue reading

#POLB Poolbeg Pharma PLC – POLB001 Data to be Presented at ASH Annual Meeting November 3, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

3 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego, California.   The ASH Annual Meeting and Exposition…

Continue reading

#POLB Poolbeg Pharma PLC – POLB 001 Oncology Programme Update Meeting November 1, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

  1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors and analysts on the POLB 001 Oncology Programme on Monday 6 November 2023 at 2:00pm – 3:30pm GMT via the Investor Meet Company platform.     The event will provide an update and greater detail on Poolbeg’s POLB 001 Oncology programme, which is…

Continue reading